Martingale Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Martingale Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-38,653	Closed	-$496K	–	872
2026 Q1	$496K	Buy	38,653 +1,700	+5%	+$21.7K	0.01%	639
2025 Q4	$332K	Sell	36,953 -5,663	-13%	-$78K	0.01%	675
2025 Q3	$736K	Sell	42,616 -1,505	-3%	-$18.5K	0.02%	550
2025 Q2	$414K	Buy	44,121 +14,322	+48%	+$118K	0.01%	645
2025 Q1	$212K	Buy	29,799 +8,400	+39%	+$84.8K	0.01%	734
2024 Q4	$250K	Buy	+21,399	New	+$334K	0.01%	715
2018 Q2	–	Sell	-31,717	Closed	-$669K	–	1006
2018 Q1	$669K	Sell	31,717 -300	-0.9%	-$7.38K	0.01%	794
2017 Q4	$616K	Sell	32,017 -290	-0.9%	-$6.7K	0.01%	790
2017 Q3	$803K	Buy	+32,307	New	+$609K	0.01%	776

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Martingale Asset Management's NTLA Position: Q2 2026 in Review

Martingale Asset Management sold out of Intellia Therapeutics (NTLA) in Q2 2026, closing a stake of 38,653 shares — an estimated $496K sold.

Martingale Asset Management first reported a position in NTLA in Q3 2017 and held it in 9 quarters. The position peaked at $803K in Q3 2017. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Martingale Asset Management reported no remaining Intellia Therapeutics position as of Q2 2026 after selling out during the quarter.
Martingale Asset Management sold 38,653 Intellia Therapeutics shares in Q2 2026, an estimated $496K.
Martingale Asset Management first reported a position in Intellia Therapeutics in Q3 2017 and held it in 9 quarters.
Martingale Asset Management's Intellia Therapeutics position peaked at $803K in Q3 2017.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.